Biomaterial Database

PDE-5 Inhibitors for BPH-Associated LUTS. 2015

Philip Brousil, and Majid Shabbir, and E Zacharakis, and Arun Sahai

Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS) are a highly prevalent problem, and with considerable burden to quality of life. Evidence has emerged that a strong correlation exists in men suffering both BPH-LUTS and erectile dysfunction (ED). Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to be highly effective in treating ED and more recently there is evidence that men with LUTS also benefit. In this review article we discuss the common pathogenic pathways of ED and LUTS, the scientific basis of PDE5i use, the efficacy of PDE5i in LUTS either as monotherapy or in combination with other established medications used in LUTS.

UI	MeSH Term	Description	Entries
D007172	Erectile Dysfunction	The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.	Impotence,Male Impotence,Male Sexual Impotence,Dysfunction, Erectile,Impotence, Male,Impotence, Male Sexual,Sexual Impotence, Male
D008297	Male		Males
D011470	Prostatic Hyperplasia	Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014563	Urodynamics	The mechanical laws of fluid dynamics as they apply to urine transport.	Urodynamic
D058986	Phosphodiesterase 5 Inhibitors	Compounds that specifically inhibit PHOSPHODIESTERASE 5.	PDE-5 Inhibitor,PDE5 Inhibitor,Phosphodiesterase 5 Inhibitor,Phosphodiesterase Type 5 Inhibitor,PDE-5 Inhibitors,PDE5 Inhibitors,Phosphodiesterase Type 5 Inhibitors,5 Inhibitor, Phosphodiesterase,Inhibitor, PDE-5,Inhibitor, PDE5,Inhibitor, Phosphodiesterase 5,Inhibitors, PDE-5,Inhibitors, PDE5,Inhibitors, Phosphodiesterase 5,PDE 5 Inhibitor,PDE 5 Inhibitors
D059411	Lower Urinary Tract Symptoms	Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM.	Lower Urinary Tract Symptom